A Downside Of Pandemic Preparedness: Wall Street May Not Value Government Contracts
Human Genome Sciences founder William Haseltine says company's stock did not move following BARDA contract for its anthrax treatment; advises industry to forget about IP for COVID-19 products.
You may also be interested in...
Under generic industry group’s proposal, the federal government would have to pay more for drugs to ensure industry investments in domestic manufacturing pay off.
Scientists and lawyers ask companies to temporarily license their IP for free, as others advocate compulsory licenses; real issue may be the ability to make a COVID-19 treatment or vaccine widely available.
Plus: Moleculin hopes to move 2-DG prodrug into clinic, India progresses niche COVID-19 defenses and more.